Pulmonary Embolism (PE) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 Pulmonary Embolism (PE) Market Outlook

Thelansis’s “Pulmonary Embolism (PE) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Pulmonary Embolism (PE) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Pulmonary Embolism (PE) Overview

Pulmonary embolism (PE) is a systemic arterial systolic pressure below 90 mmHg that does not respond to pressor agents. PE is often called “the great masquerader” due to its ability to mimic the signs and symptoms of other diseases. The majority of clinically significant PEs originate from venous thromboembolisms (VTEs) that develop in the lower extremities or pelvic veins. In rarer cases, upper extremity thromboembolic events can result in PE. The development of VTE is associated with various conditions. Virchow’s triad, consisting of hypercoagulability, venous stasis, and vessel wall injury, provides a model for understanding many risk factors. These factors can be either inherited or acquired. Major risk factors for thromboembolic events include recent immobilization, myocardial infarction (MI), cerebrovascular accident (CVA), surgery, and trauma. Failure to diagnose PE is a severe management error, as untreated patients have a mortality rate of 30%, whereas, with effective therapy, the mortality rate decreases to 8%. PE can be asymptomatic or present with sudden death. Common signs include tachypnea (54%) and tachycardia (24%). The most frequently reported symptoms are dyspnea, often occurring within seconds, either at rest or during exertion (73%), pleuritic pain (44%), calf or thigh pain (44%), calf or thigh swelling (41%), and cough (34%). Treatment options for PE include thrombolysis and anticoagulation using heparins and oral vitamin K antagonists. A minority of patients do not experience clot resolution and subsequently develop chronic thromboembolic disease.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Pulmonary Embolism (PE) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034